Prelude Capital Management’s bluebird bio BLUE Stock Holding History

Prelude Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,333	Closed	-$84.8K	–	1135
2023 Q1	$84.8K	Buy	+1,333	New	+$152K	0.01%	966
2021 Q3	–	Sell	-523	Closed	-$217K	–	1757
2021 Q2	$217K	Buy	+523	New	+$207K	0.01%	1349
2020 Q4	–	Sell	-488	Closed	-$341K	–	1325
2020 Q3	$341K	Sell	488 -254	-34%	-$198K	0.02%	522
2020 Q2	$586K	Buy	742 +688	+1,274%	+$519K	0.03%	438
2020 Q1	$32K	Sell	54 -51	-49%	-$49.7K	﹤0.01%	865
2019 Q4	$119K	Buy	+105	New	+$114K	﹤0.01%	1034
2019 Q2	–	Sell	-162	Closed	-$280K	–	1692
2019 Q1	$331K	Buy	+162	New	+$285K	0.02%	581
2018 Q3	–	Sell	-9	Closed	-$17K	–	1736
2018 Q2	$17K	Buy	+9	New	+$20.5K	﹤0.01%	1380
2017 Q4	–	Sell	-99	Closed	-$175K	–	1371
2017 Q3	$175K	Buy	+99	New	+$138K	0.02%	693
2015 Q4	–	Sell	-263	Closed	-$291K	–	1459
2015 Q3	$291K	Hold	263	–	–	0.04%	446
2015 Q2	$573K	Sell	263 -31	-11%	-$63.2K	0.08%	281
2015 Q1	$459K	Buy	+294	New	+$388K	0.06%	369

Other funds holding BLUE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Prelude Capital Management's BLUE Position: Q2 2023 in Review

Prelude Capital Management sold out of bluebird bio (BLUE) in Q2 2023, closing a stake of 1,333 shares — an estimated $84.8K sold.

Prelude Capital Management first reported a position in BLUE in Q1 2015 and held it in 12 quarters. The position peaked at $586K in Q2 2020. 175 funds tracked by Wall St. Rank hold BLUE as of Q2 2023.

Prelude Capital Management reported no remaining bluebird bio position as of Q2 2023 after selling out during the quarter.
Prelude Capital Management sold 1,333 bluebird bio shares in Q2 2023, an estimated $84.8K.
Prelude Capital Management first reported a position in bluebird bio in Q1 2015 and held it in 12 quarters.
Prelude Capital Management's bluebird bio position peaked at $586K in Q2 2020.
175 funds tracked by Wall St. Rank held bluebird bio as of Q2 2023.

Based on Prelude Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.